Daniel Landau, MD

Daniel Landau, MD, is a hematologist/oncologist at the Medical University of South Carolina.

Articles

PARP Inhibition in Metastatic CRPC: The PROfound and TRITON2 Studies

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

August 8th 2022

Expert perspectives on the PROfound and TRITON2 studies of olaparib and rucaparib, respectively, in metastatic castration-resistant prostate cancer.

Looking Toward Future Management Strategies in Prostate Cancer

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

August 8th 2022

Closing out their discussion on novel treatment approaches in prostate cancer, experts consider future strategies and remaining unmet needs in this setting.

Testing for Germline/Somatic BRCA Mutations in Metastatic CRPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

August 8th 2022

A brief discussion on the importance of germline/somatic BRCA1 and BRCA2 mutations in metastatic CRPC, accompanied by practical advice on genetic testing.

VISION Trial: 177 Lu-PSMA-617 in Metastatic CRPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

August 1st 2022

Shared insight on the VISION trial, which analyzed 177 Lu-PSMA-617 in previously treated PSMA-positive metastatic castration-resistant prostate cancer.

Case 3: A 70-Year-Old Man With Metastatic CRPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

August 1st 2022

Moving on to their last patient case, expert panelists review the diagnosis and management of a patient with metastatic castration-resistant prostate cancer.

Metastatic CSPC: Educating Patients and Addressing Unmet Needs

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

July 25th 2022

Before closing out their discussion on metastatic CSPC, expert oncologists consider how best to educate patients and address the remaining unmet needs in this setting.

ARASENS Trial: Darolutamide-Containing Triplet Therapy for mCSPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

July 25th 2022

After reviewing data from the ARASENS trial, experts consider the role of the daralutamide-containing triplet regimen in metastatic CSPC.

Case 2: A 72-Year-Old Man With Metastatic CSPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

July 18th 2022

Key opinion leaders review the case of a 72-year-old man with metastatic CSPC and consider optimal treatment approaches in this setting.

Optimizing Management of Nonmetastatic CRPC: Darolutamide Therapy

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

July 18th 2022

Comprehensive insight on darolutamide therapy in nonmetastatic CRPC, supported by clinical data from the ARAMIS trial.

Factors in Selecting Therapy for Nonmetastatic CRPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

July 11th 2022

Shared insight on how expert oncologists select therapy for patients with nonmetastatic castration-resistant prostate cancer.

Practical Advice on Novel Imaging Strategies in Nonmetastatic CRPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

July 11th 2022

Expert perspectives on optimal patient follow-up, with particular regard for PSMA imaging, in nonmetastatic castration-resistant prostate cancer.

Frontline Treatment Approaches to Nonmetastatic CRPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

July 4th 2022

Returning to the patient case, experts review available frontline treatment options in the setting of nonmetastatic castration-resistant prostate cancer.

Nonmetastatic CRPC: Importance of Patient Risk Status and Genetic Testing

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

July 4th 2022

A brief review of the prevalence of familial risk and other high-risk factors for prostate cancer, followed by recommendations for patient follow-up and genetic testing.

Case 1: A 59-Year-Old Man With Nonmetastatic CRPC

Alan Bryce, MD;Eleni Efstathiou, MD;Daniel Landau, MD

June 27th 2022

Panelists center their discussion on a real-world patient case of nonmetastatic castration-resistant prostate cancer managed with surgery and adjuvant therapy.